Evithrom market report forecasts growth through 2035

The Business Research Company says the global Evithrom market is poised for growth through 2035, driven by more surgeries, trauma cases, and broader use of human thrombin products in bleeding control. North America led the market in 2025, while Europe is expected to grow fastest in the coming years.

Why it matters: - Evithrom is used to control bleeding during surgery, making it relevant to hospitals, surgeons, and patients in high-risk procedures. - The market’s growth is tied to rising surgical volumes, trauma care needs, and demand for faster clotting agents. - The report points to expanding use across cardiovascular, orthopedic, and spinal surgeries.

What happened: - The Business Research Company released its "Detailed Evithrom Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035." - The report says the Evithrom market is expected to expand over the forecast period as surgical procedures increase worldwide. - A free sample of the report is available here. - The full report is available here.

The details: - Evithrom is a topical hemostatic agent made from human thrombin and fibrinogen. - The product is designed to manage bleeding effectively during surgery. - Evithrom is used across a wide range of procedures, with particular application in cardiovascular and orthopedic surgeries. - The report cites past market support from high surgical blood-loss risk, urgent demand for fast-acting hemostatic agents, early adoption of thrombin-based products, rising trauma cases, and greater use in orthopedic surgery. - Future growth is linked to more surgical interventions, higher accident and trauma rates, hospital infrastructure improvements, thrombin formulation innovations, and stronger surgical safety protocols. - Key trends in the forecast period include broader use of topical hemostatic agents, rising demand in cardiovascular surgery, growth in trauma and emergency care services, preference for rapid-clotting agents, and greater uptake of human thrombin products. - The report says the market analysis covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - New analytical features in the 2026 report include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis, and updated graphics and tables.

Between the lines: - The report’s growth thesis centers on procedures that require tighter bleeding control, which gives Evithrom exposure to multiple surgical categories rather than one niche use. - Personalized medicine is becoming a supportive theme because human thrombin products fit more tailored hemostatic management. - The report highlights a shift from broad surgical demand toward more specific use cases in trauma, cardiovascular care, and spinal surgery. - In 2023, the U.S. Food and Drug Administration approved 16 new personalized therapies for rare diseases, up from six in 2022, underscoring wider momentum for individualized treatment approaches. - The International Society of Aesthetic Plastic Surgery reported in June 2024 that liposuction was the most commonly performed surgery in 2023 with more than 2.2 million cases, and face and head procedures rose 19.6% to more than 6.5 million. - The Congressionally Directed Medical Research Programs said in October 2024 that about 300,000 people in the U.S. live with spinal cord injuries, with more than 17,000 new cases annually.

What's next: - North America held the largest Evithrom market share in 2025. - Europe is forecast to post the fastest growth in the coming years. - The report expects continued market expansion as hospitals, surgeons, and emergency-care systems rely more on hemostatic products to reduce bleeding risk. - The Business Research Company says the report’s added analytics are meant to help buyers track market hotspots, technology shifts, and forecast scenarios more closely.